In this report, the Bioresorbable Coronary Stents Market has been segmented by Brand, Material, Drug, End Use, and Geography.

Bioresorbable Coronary Stents Market, Segmentation by Brand

The Bioresorbable Coronary Stents Market has been segmented by Brand into Absorb BVS, Absorb 2nd Generation, Magmaris, Magnitude, MeRes-100, and DESolve.

Absorb BVS
Absorb BVS, the pioneering FDA-approved bioresorbable stent, introduced a revolutionary concept of temporary vascular scaffolding. While it once dominated with over 60% market share, concerns over scaffold thrombosis led to its gradual market exit. Its legacy, however, set the stage for innovation in the bioresorbable stent space.

Absorb 2nd Generation
The Absorb 2nd Generation stent was developed to overcome the limitations of its predecessor. It features enhanced polymer integrity and improved resorption rates, resulting in a 15–20% reduction in late-stage thrombosis. These improvements have contributed to renewed clinician confidence and broader adoption.

Magmaris
Magmaris stands out for its magnesium-based composition, offering superior mechanical performance and rapid bioresorption. Its resorption rate is about 30% faster than traditional polymer-based stents, making it a preferred option in regions prioritizing fast vascular restoration and biocompatibility.

Magnitude
Magnitude is recognized for its ultra-thin strut structure, designed to promote quicker vascular healing and reduce restenosis. Leveraging next-generation biomaterials, it shows a 25% improvement in vascular response, particularly gaining popularity in cost-sensitive and emerging markets.

MeRes-100
Developed in India, MeRes-100 has emerged as a clinically validated and cost-efficient solution for bioresorbable stenting. It has demonstrated a 20% reduction in MACE (Major Adverse Cardiac Events) at the 12-month mark, positioning it as a viable option for high-volume healthcare systems.

DESolve
The DESolve stent features a self-correcting polymer matrix, engineered to provide controlled degradation and optimal vessel support. It has shown 15–18% gains in late lumen diameter, highlighting its strength in maintaining vessel patency while naturally resorbing over time.

Bioresorbable Coronary Stents Market, Segmentation by Material

The Bioresorbable Coronary Stents Market has been segmented by Material into Polymer, and Metal.

Polymer
Polymer-based bioresorbable coronary stents lead the market, comprising around 70% of total usage. Known for their biocompatibility and controlled resorption, these stents are typically made from polylactic acid (PLA) or similar materials. While they provide predictable performance, concerns over late-stage thrombosis have prompted innovations to enhance safety and efficacy.

Metal
Metal bioresorbable stents, particularly those made from magnesium alloys, are emerging as a strong alternative. With a market share nearing 30%, they offer 30–40% faster degradation than their polymer counterparts, along with enhanced mechanical stability. These features make them ideal for patients requiring rapid vascular healing and scaffold clearance.

Bioresorbable Coronary Stents Market, Segmentation by Drug

The Bioresorbable Coronary Stents Market has been segmented by Drug into Sirolimus and Novalimus.

Sirolimus
Sirolimus-eluting bioresorbable stents are the leading choice in drug-coated technologies, capturing nearly 75% of the market. Their strong anti-proliferative properties help minimize restenosis and reduce the need for repeat procedures. Studies indicate a 30–40% reduction in TLR (Target Lesion Revascularization), positioning Sirolimus as a highly effective solution in long-term vascular outcomes.

Novalimus
Novalimus-based stents are an emerging alternative, known for their optimized drug-release kinetics and support for faster endothelial healing. With a current market share of around 25%, they are becoming popular due to 20–25% lower inflammation rates and encouraging clinical data on post-implantation recovery and performance.

Bioresorbable Coronary Stents Market, Segmentation by End Use

The Bioresorbable Coronary Stents Market has been segmented by End Use into Outpatient and Inpatient Facilities.

Outpatient Facilities
Outpatient facilities have become the preferred setting for bioresorbable stent procedures, driven by the shift toward minimally invasive care and reduced hospitalization. Holding about 55% of the market, these centers are favored for their efficient workflows, shorter patient stays, and lower healthcare costs, aligning with modern patient-centric care models.

Inpatient Facilities
Inpatient facilities continue to be indispensable for managing complex cardiac cases requiring extensive care. With a 45% share of the market, these facilities offer advanced post-operative support, continuous monitoring, and the ability to handle high-risk interventions, ensuring patient safety in more critical scenarios.

Bioresorbable Coronary Stents Market, Segmentation by Geography

In this report, the Bioresorbable Coronary Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Bioresorbable Coronary Stents Market Share (%), by Geographical Region

North America
North America leads the bioresorbable coronary stents market, generating nearly 35% of the total revenue. The region’s edge lies in its technologically advanced healthcare systems, early adoption of medical innovations, and supportive regulatory frameworks that encourage rapid commercialization of novel stent solutions.

Europe
Europe commands roughly 28% of the global share, supported by strong clinical research, particularly in magnesium-based bioresorbable stents. With public health systems backing innovative cardiovascular treatments, countries like Germany, France, and the UK are key contributors to regional market expansion.

Asia Pacific
Asia Pacific emerges as the most dynamic region, capturing 22% of the market and growing rapidly due to surging cardiovascular cases and rising healthcare accessibility. Countries like India, China, and Japan are leading adoption thanks to domestic manufacturing, affordability, and strategic government support.

Middle East and Africa
Middle East and Africa account for about 8% of the market, with growth propelled by increasing access to interventional cardiology services and infrastructure upgrades. Countries like the UAE and South Africa are seeing improved penetration of bioresorbable stent technologies.

Latin America
Latin America contributes approximately 7% to the global market. Brazil and Mexico dominate regional sales, supported by a rise in healthcare privatization, expansion of minimally invasive cardiac procedures, and increased government funding toward cardiovascular disease management.